Second, we assessed the functionality of our FOLR1-specific CAR T cells against patient-derived tumor cells in an autologous setup, i.e., tumor cells, CAR T cells, as well as ascites derived from the same patient. This evidence concerns the gene FOLR1 and neoplasm.